Related Experiment Video
Updated: Jun 29, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Discovery of the First Potent DYRK2 Proteolysis Targeting Chimera Degraders
Jian Chen1, Wentao Zhu1, Wenqian Zhang1
1School of Chemistry, Sun Yat-sen University, Guangzhou 510275, China.
Abstract:
Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) has been identified as a promising oncogenic driver of several types of cancer and is considered to be a critical cancer therapeutic target. Several inhibitors of DYRK2 have been reported, but no degraders have been found yet. In this work, we designed and synthesized the first series of proteolysis-targeting chimeras (PROTACs) using curcumin and its analogs as warheads to target and degrade DYRK2. The results of degradation assays showed that the compound CP134 could effectively downregulate the intracellular DYRK2 level (DC50 = 1.607 μM). Further mechanism of action experiments revealed that CP134 induced DYRK2 degradation through the ubiquitin-proteasome system. Altogether, CP134 disclosed in this study is the first potent DYRK2 degrader, which could serve as a valuable chemical tool for further evaluation of its therapeutic potential, and our results broaden the substrate spectrum of PROTAC-based degraders for further therapeutic applications.
Insights
Researchers developed the first proteolysis-targeting chimeras (PROTACs) to degrade Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2), a cancer target. The compound CP134 effectively reduced DYRK2 levels via the ubiquitin-proteasome system.
Area of Science:
- Oncology
- Molecular Biology
- Medicinal Chemistry
Background:
- DYRK2 is an oncogenic driver in multiple cancers, making it a key therapeutic target.
- Existing DYRK2 inhibitors are available, but no degraders have been developed.
- Targeting protein degradation offers a novel therapeutic strategy.
Purpose of the Study:
- To design and synthesize the first series of PROTACs targeting DYRK2.
- To evaluate the efficacy of these PROTACs in degrading DYRK2.
- To investigate the mechanism of action for DYRK2 degradation.
Main Methods:
- PROTACs were designed using curcumin analogs as warheads.
- Degradation assays were performed to assess intracellular DYRK2 levels.
- Mechanism of action studies utilized the ubiquitin-proteasome system.
Main Results:
- The compound CP134 effectively degraded intracellular DYRK2 with a DC50 of 1.607 μM.
- CP134-induced degradation of DYRK2 occurred via the ubiquitin-proteasome pathway.
- This study presents the first potent DYRK2 degrader.
Conclusions:
- CP134 is the first identified potent degrader of DYRK2.
- CP134 serves as a valuable chemical tool for exploring DYRK2's therapeutic potential.
- This work expands the application of PROTACs to new substrate targets.
Related Concept Videos
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Anaphase Promoting Complex
Export of Misfolded Proteins out of the ER
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...

